Compass Pathways has announced that it will be replacing its chief executive officer by the end of the month. The company’s founder, CEO and chair, George Goldsmith, will be replaced as CEO by Kabir Nath, effective Aug. 1, 2022.
The mental health company announced on its website that George Goldsmith will continue serving as executive chair from Aug. 1 to Dec. 31, 2022, to assist in the transition. Goldsmith will retain his position as the executive chair once the handover is complete. He cofounded Compass Pathways PLC (NASDAQ: CMPS) in 2016 and led the firm from a startup to a leader in the psychedelics mental health care segment.
A veteran in the health care industry, Nath is an experienced pharmaceutical leader who will bring a wealth of knowledge to Compass. He was previously the senior managing director of global pharmaceuticals company Otsuka Pharmaceutical Co. Ltd. Before that, Nath served as the president and CEO of Otsuka North America Pharmaceutical Business, leading the development of digital solutions and pharmaceutical products to address mental health needs.
Coincidentally, Otsuka has invested in Compass in the past and has dabbled in the psychedelics game, partnering with Atai Life Sciences, which has a 20.7% stake in Compass, and Mindset Pharma. Nath also held a variety of positions at the global pharmaceutical firm Bristol Meyers Squibb. The New York-based company developed novel medications for patients afflicted with serious medical conditions.
With his experience as a Big Pharma leader, Nath has a history of leading companies in the pharmaceutical space, and he is intimately aware of the complexities involved in drug development.
According to current Goldsmith, Compass Pathways was founded to “transform mental health care” via predictive, preventative and personalized models of care. He stated that Nath had a proven track record of successful business growth coupled with a deep dedication to developing effective treatment strategies. Goldsmith added that Nath would leverage his experience in the pharmaceutical game and collaborate with the leadership at Compass Pathways to commercialize the company’s COMP360 psilocybin therapy and bring the groundbreaking therapy to patients who aren’t benefiting from current treatment strategies.
Nath revealed that he was fortunate enough to develop a working relationship with the outgoing CEO, cofounder Ekaterina Malievskaia, and other members of the leadership team and board members after Otsuka’s investment in Compass. He expressed a “deep appreciation” for the Compass team’s commitment to developing accessible and science-based treatment options for some of the most severe mental health conditions in the world.
About PsychedelicNewsWire
PsychedelicNewsWire (PNW) is a specialized content distribution company that (1) aggregates and distributes news and information on the latest developments in all aspects and advances of psychedelics and their use, (2) creates PsychedelicNewsBreaks designed to quickly update investors on important industry news, (3) leverages a team of expert editors to enhance press releases for maximum impact, (4) assists companies with the management and optimization of social media across a range of platforms, and (5) delivers unparalleled corporate communication solutions. PNW stays abreast of the latest information and has established a reputation as the go to source for coverage of psychedelics, therapeutics and emerging market opportunities. Our team of seasoned journalists has a proven track record of helping both public and private companies gain traction with a wide audience of investors, consumers, media outlets and the general public by leveraging our expansive dissemination network of more than 5,000 key syndication outlets. PNW is committed to delivering improved visibility and brand recognition to companies operating in the emerging markets of psychedelics.
To receive instant SMS alerts, text “Groovy” to 844-397-5787 (U.S. Mobile Phones Only)
For more information please visit https://www.PsychedelicNewsWire.com
Please see full terms of use and disclaimers on the PsychedelicNewsWire website applicable to all content provided by PNW, wherever published or re-published: https://www.PsychedelicNewsWire.com/Disclaimer
Do you have questions or are you interested in working with PNW? Ask our Editor
PsychedelicNewsWire (PNW)
San Francisco, California
www.PsychedelicNewsWire.com
415.949.5050 Office
Editor@PsychedelicWire.com
PsychedelicNewsWire is part of the InvestorBrandNetwork.